La chaîne d'options affiche les données clés des options sur actions de Nu Skin Enterprises à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Nu Skin Enterprises..

Nu Skin Enterprises (NYSE:NUS) Stock, Chaîne d'Options

Nu Skin Enterprises

Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.

Nu Skin Enterprises Inc

Nuveen ESG 1-5 Year U.S. Aggregate Bond ETF

Nuveen Ultra Short Income ETF

Nuveen ESG Small-Cap ETF

NEOS Nasdaq-100 Hedged Equity Income ETF

NAUTILUS MINERALS INC ORD by Nautilus Minerals Inc.

NEW SOURCE ENGY PFD UTS by New Source Energy Partners LP

U.S. stocks were higher, with the Dow Jones index gaining over 100 points on Friday.
Shares of Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) rose sharply during Friday's session. The company disclosed its production and delivery figures for the fourth quarter and <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42786671/why-is-rivian-automotive-stock-surging-today">full-year 2024</a>.
The company reported a 1.5% year-on-year rise in its fourth-quarter deliveries to 14,183 vehicles. The company produced 12,727 vehicles at its Normal, Illinois facility. The delivery numbers are in contrast to 10,018 electric vehicles in the third quarter, which was the lowest number of quarterly deliveries since the first quarter of 2023.
Rivian Automotive shares jumped 17.9% to $15.63 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Cerence Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) shares jumped 56.1% to $12.39 after the company announced an expanded collaboration with NVIDIA to advance its CaLLM family of language models.</li>
<li>Quantum-Si incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) gained 27.7% to $5.44.</li>
<li>Nu Skin Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) shares jumped 21.8% to $7.99 after the company announced its subsidiary sold the Mavely affiliate marketing platform for $250 million in a mixed cash and equity deal.</li>
<li>Neumora Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) shares surged 21.1% to $2.3850. HC Wainwright &amp; Co. analyst Douglas Tsao reiterated Neumora Therapeutics with a Buy and maintained a $30 price target.</li>
<li>Acelyrin, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>) gained 18.8% to $3.92 after the company announced it will reveal new Phase 2 results and Phase 3 plans for Subcutaneous Lonigutamab during a hosted virtual investor event.</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) jumped 18.1% to $17.44.</li>
<li>Amprius Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NASDAQ">AMPX</a>) gained 17.8% to $3.3688.</li>
<li>KULR Technology Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) rose 16.4% to $3.5150.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) surged 15.3% to $9.33.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) gained 14.2% to $10.94.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) gained 11.8% to $24.43.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) rose 8.4% to $27.06.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) surged 8.1% to $19.14.</li>
<li>Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) gained 8.1% to $11.31.</li>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) rose 5.7% to $3.2050.</li>
<li>Vistra Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VST#NASDAQ">VST</a>) gained 5% to $156.96 after UBS raised its price target on the stock from $161 to $174.</li>
<li>Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) rose 4.6% to $90.76 after Raymond James upgraded the stock from Market Perform to Outperform and announced a price target of $115.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/01/42785203/tesla-to-351-here-are-10-top-analyst-forecasts-for-friday">Tesla To $351? Here Are 10 Top Analyst Forecasts For Friday</a></li>
</ul>

News

Intraday Update

Markets

Trading Ideas

ACHR

AMPX

CRNC

JOBY

KULR

LCID

NMRA

OKLO

RIOT

RIVN

RKLB

SERV

SLRN

Rivian Automotive, Cerence, Nu Skin Enterprises And Other Big Stocks Moving Higher On Friday

WIIM

Nu Skin Enterprises shares are trading higher after the company announced its subsidiary sold the Mavely affiliate marketing platform for $250 million in a mixed cash and equity deal.

Nu Skin Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) saw its shares rise on Friday following the announcement of a strategic transaction <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">by its Rhyz Inc. subsidiary.</a>
Rhyz has sold its Mavely affiliate marketing technology platform to Later, a portfolio company of Summit Partners, for approximately $250 million in cash and a minority equity stake in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42781900/nu-skin-enterprises-announces-strategic-transaction-of-mavely-for-250-million" rel="noreferrer noopener">combined Later/Mavely business.</a>
The deal, which also includes $33 million to be paid to other equity holders in the Mavely business, is part of Nu Skin&#8217;s broader strategy to enhance its affiliate marketing efforts. Despite the sale, Mavely will continue to provide technology and social commerce capabilities to support Nu Skin&#8217;s affiliate marketing business.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42782379/asia-markets-mixed-while-europe-dips-gold-flat-and-oil-prices-ease-slightly-global-markets-today-while-us-slept" rel="noreferrer noopener">Dollar Hits New 2-Year High; Asia Markets Mixed, Europe Dips &#8211; Global Markets Today While Us Slept</a>
Ryan Napierski, Nu Skin&#8217;s president and CEO, expressed confidence in the transaction, highlighting how the combination of Later and Mavely will help accelerate the company&#8217;s vision for its beauty, wellness, and lifestyle ecosystem. Napierski also noted that the deal strengthens Nu Skin&#8217;s balance sheet, generating additional capital to increase innovation in its core business and investments in Rhyz companies.
This strategic move has resulted in an approximate five-times return on Nu Skin&#8217;s cumulative investment in Mavely since its acquisition in 2021. The proceeds from the transaction are expected to be used for debt reduction, further innovation, and stock buybacks under Nu Skin&#8217;s repurchase program, aiming to provide value to its shareholders.
Price Action: NUS shares are trading higher by 16.5% to $7.64 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42779827/joe-biden-to-decide-on-nippon-steels-14-9b-us-steel-acquisition-on-friday-amid-veto-offer-labor-concerns" target="_blank" rel="noreferrer noopener">Joe Biden To Decide On Nippon Steel&#8217;s $14.9B US Steel Acquisition On Friday Amid Veto Offer, Labor Concerns</a></li>
</ul>
Photo via Shutterstock.

Equities

Asset Sales

Movers

General

Why Is Nu Skin Enterprises Stock Jumping Today?

Approximately $33 million of such consideration will be paid to other equity holders in the Mavely business. In connection with the transaction, Mavely is expected to continue to provide certain technology and social commerce capabilities to support Nu Skin's affiliate marketing business.
"Together, we believe Later and Mavely will provide enhanced capabilities to our company as we pursue our broader beauty, wellness and lifestyle ecosystem vision, while the transaction generates additional capital and resources for us to increase innovation in our core Nu Skin business and investment in our Rhyz companies," said Ryan Napierski, Nu Skin president and CEO. "This underscores the value of Rhyz to incubate and scale meaningful businesses with synergistic value across the enterprise."
This transaction generated an approximate five-times return on the company's cumulative investment in Mavely since it was acquired in 2021. Proceeds from the transaction are expected to be used to pay down debt and fund additional innovation. The company also plans to use its strengthened balance sheet to buy back stock under its existing stock repurchase program, providing value to its shareholders.
Evercore Group LLC acted as exclusive financial advisor and Simpson Thacher &amp; Bartlett LLP acted as legal counsel to Nu Skin Enterprises.

Nu Skin Enterprises' Rhyz Subsidiary Sells Mavely Affiliate Marketing Platform To Later For $250M In Cash and Equity, Retains Minority Stake In Combined Later/Mavely Business

DA Davidson analyst Linda Bolton Weiser maintains Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) with a Neutral and lowers the price target from $11 to $7.

Price Target

Analyst Ratings

DA Davidson Maintains Neutral on Nu Skin Enterprises, Lowers Price Target to $7

Guidance

Nu Skin Sees Q4 Adj. EPS $0.19-$0.29 vs $0.28 Est., Revenue $410M-$445M vs $455.83M Est.; Sees 2024 Adj. EPS $0.65-$0.75 vs $0.77 Est., Revenue $1.7B-$1.73B vs $1.75B Est.

Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.14 by 21.43 percent. The company reported quarterly sales of $430.100 million which missed the analyst consensus estimate of $440.954 million by 2.46 percent. This is a 13.77 percent decrease over sales of $498.772 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Nu Skin Enterprises Q3 2024 GAAP EPS $0.17 Beats $0.14 Estimate, Sales $430.100M Miss $440.954M Estimate

Nu Skin Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nus#NYSE">NUS</a>) is driving its growth strategy through key initiatives that aim to revitalize its market presence and tap into high-growth areas. The company continues to prioritize thoughtful product introductions that align with shifting consumer preferences. A recent example is the launch of MYND360, a new line of clinically validated nutritional formulas tailored to support cognitive well-being.
Featuring six products, MYND360 is designed to enable users to manage stress, remain focused, enhance memory and sleep better. This innovation reflects Nu Skin&#39;s focus on the fast-growing brain health market. While these upsides, along with strength in the Rhyz business, have been working well. Nu Skin remains troubled by persistent macroeconomic obstacles.
<h2>Product Launches a Key Driver for Nu Skin</h2>
With the help of advanced technology and well-strategized product programs, Nu Skin tries to capture greater market share and maintain growth momentum. The company&#39;s long-term strategies stand on three key pillars &mdash; Products, Programs and Platforms. NUS has been successfully launching innovative beauty devices, which have become an important part of its growth.
Nu Skin&#39;s second-quarter 2024 results included positive contributions from new products such as Ageloc, Wellspa IO and RenewspA IO, along with the company&#39;s TRME weight management system. The ageLOC WellSpa iO has been a solid addition to the company&#39;s beauty device system brands, generating impressive response.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/78/81418.jpg?v=533402966" />
Image Source: Zacks Investment Research
<h2>Nu Skin Gains From Rhyz Business</h2>
Nu Skin&#39;s Rhyz business emerges as a cornerstone of its strategic vision, highlighted by its remarkable growth trajectory and significant contribution to the company&#39;s revenue stream. Rhyz represents a cohesive ecosystem comprising consumer, technology, and manufacturing entities, all dedicated to pioneering innovation within the realms of beauty, wellness, and lifestyle. Experiencing 32.3% revenue growth in the second quarter of 2024, Rhyz accounted for 15% of total enterprise revenues and is anticipated to reach 20% to 25% by 2025.
The success of this business reflects Nu Skin&#39;s commitment to capitalizing on evolving consumer trends, particularly in influencer and affiliate marketing, which are projected to surge in the coming years. By investing in Rhyz&#39;s manufacturing capabilities, technology advancements, and creator-led indie beauty brands, Nu Skin is strategically positioning itself to drive sustained growth and value creation within the beauty, wellness, and lifestyle market.
<h2>Challenges Faced by NUS</h2>
Nu Skin&#39;s second-quarter 2024 performance was hurt by continuous macroeconomic headwinds across most regions, which weighed on consumer spending and customer acquisition, especially for premium products. The company also grappled with pressures in the direct selling industry. These headwinds, along with foreign adverse currency fluctuations, hurt Nu Skin&#39;s quarterly revenues, which tumbled 12.2% year over year to $439.1 million in the second quarter.
The operating environment for Nu Skin&#39;s core business remains challenging, primarily due to macroeconomic factors and pressures within the direct selling industry. Taking into account the company&#39;s first-half 2024 performance and rising foreign exchange headwinds, management tightened the annual guidance range for 2024 in its second-quarter earnings release.
Nu Skin now anticipates revenues in the band of $1.73-$1.81 billion for 2024, which suggests a 12-8% decline from the year-ago period&#39;s reported figure. Earlier, the metric was expected to be in the range of $1.73-$1.87 billion. Management envisions adjusted earnings per share of 75-95 cents. The projection suggests a decline from adjusted earnings of $1.85 recorded in 2023. Management had earlier envisioned an adjusted EPS of 95 cents to $1.35 for 2024.
For the third quarter of 2024, the company expects revenues between $430 million and $465 million, which suggests a decline of 14% to 7% from the year-ago quarter&#39;s reported level. The company expects adjusted EPS of 15-25 cents in the third quarter of 2024 compared with 56 cents recorded in the same period last year. Shares of NUS have plunged 42.6% in the past three months compared with the industry&#39;s decline of 10%.
<h2>Final Words on NUS</h2>
Nu Skin continues to drive growth through strategic initiatives, innovative product launches, and the expanding Rhyz business. While the company has made significant strides in capturing market opportunities, especially in the beauty and brain health sectors, it faces ongoing challenges from macroeconomic pressures and headwinds in the direct selling industry. Moving forward, the Zacks Rank #3 (Hold) company&#39;s ability to balance innovation with market realities will be key to sustaining its growth trajectory.
<h2>Top 3 Staple Bets</h2>
Inter Parfums (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipar#NASDAQ">IPAR</a>) is engaged in the manufacturing, distribution and marketing of a wide range of fragrances and related products. It currently carries a Zacks Rank of 2 (Buy).
The Zacks Consensus Estimate for IPAR&#39;s current financial-year sales and earnings indicates advancements of 10.2% and 8.4%, respectively, from the prior-year figures. It has a trailing four-quarter earnings surprise of 2.5%, on average.
Flowers Foods (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/flo#NYSE">FLO</a>), one of the largest producers of packaged bakery foods in the United States, currently carries a Zacks Rank #2. FLO has a trailing four-quarter earnings surprise of 1.9%, on average.
The Zacks Consensus Estimate for Flowers Foods&#39; current financial-year sales and earnings implies growth of around 1% and 5%, respectively, from the year-ago reported numbers.
McCormick &amp; Company, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mkc#NYSE">MKC</a>) is a leading manufacturer, marketer and distributor of spices, seasonings, specialty foods and flavors. It currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for McCormick &amp; Company&#39;s current fiscal-year sales and earnings indicates advancements of 0.6% and 8.2%, respectively, from the year-ago reported figures. MKC has a trailing four-quarter earnings surprise of 13.8%, on average.
<a href="https://www.zacks.com/stock/news/2351561/nu-skin-navigates-growth-with-innovation-amid-industry-challenges?cid=CS-BENZ-FT-analyst_blog|rank_focused-2351561">To read this article on Zacks.com click here.</a>

Large Cap

Macro Economic Events

Mid Cap

Small Cap

Management

Economics

IPAR

Nu Skin Navigates Growth With Innovation Amid Industry Challenges

MYND360 provides holistic, cognitive support for core areas of mental well-being, including sleep, calm, focus and memory
Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>), a global beauty and wellness leader, today introduced MYND360, a new line of clinically proven nutritional formulas to support core needs for cognitive well-being. MYND360 is the culmination of five years of research and clinical studies, and features six products designed to help users sleep better, manage stress, stay focused and even support a strong memory.

Biotech

Nu Skin Introduces MYND360, A New Line Of Clinically Proven Supplements And Topicals For Mental Well-Being

Nu Skin Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nus#NYSE">NUS</a>) has not been in its best shape lately, with its shares down 27.7% in the past three months compared with the industry&#39;s 21.3% decline. Additionally, this beauty and wellness product company has trailed the broader Zacks Consumer Staples sector and the S&amp;P 500&#39;s respective growth of 1.2% and 4.2%.
Despite being a prominent player in the beauty and wellness industry, Nu Skin has struggled to navigate a series of macroeconomic headwinds that have dampened consumer spending, particularly on premium products. Additionally, the company has been severely impacted by stronger-than-expected foreign currency fluctuations and ongoing pressures within the direct selling industry, contributing to a disappointing second-quarter 2024 performance.
Considering the company&#39;s first-half 2024 performance and rising foreign exchange headwinds, management tightened the annual guidance range for 2024 in its second-quarter earnings release.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a3/74745.jpg?v=1909197970" />
Image Source: Zacks Investment Research
<h3>Macroeconomic Hurdles Persist</h3>
Nu Skin has been encountering persistent macroeconomic obstacles, which continued in the second quarter of 2024. The company&#39;s performance was hurt by continuous macroeconomic headwinds across most regions, which weighed on consumer spending and customer acquisition, especially for premium products. Additionally, NUS grappled with pressures in the direct selling industry.
These headwinds, along with foreign adverse currency fluctuations, hurt Nu Skin&#39;s quarterly revenues, which tumbled 12.2% year over year to $439.1 million in the second quarter. On a constant-currency basis, revenues fell 8%.&nbsp; Sales leaders were down 16% year over year to 38,592. Nu Skin&#39;s customer base dropped 14% to 893,514. The company&#39;s paid affiliates were down 17% to 155,486. On an adjusted basis, paid affiliates tumbled 9%.
<h3>Volatile Currency Movements</h3>
Nu Skin&#39;s strong international presence exposes it to the risk of volatile currency movements. Any adverse currency fluctuation is likely to weigh on the company&#39;s operating performance. Nu Skin&#39;s second-quarter 2024 revenues witnessed strong currency headwinds. Revenues included a negative impact of 4.2% from foreign currency fluctuations. The company envisions unfavorable foreign currency impacts of around 4-3% on third-quarter and 2024 revenues.
<h3>Bumpy Road Ahead</h3>
The operating environment for Nu Skin&#39;s core business remains challenging, primarily due to macroeconomic factors and pressures within the direct selling industry. Nu Skin now anticipates revenues in the band of $1.73-$1.81 billion for 2024, which suggests a 12-8% decline from the year-ago period&#39;s reported figure. Earlier, the metric was expected in the range of $1.73-$1.87 billion. Management envisions an adjusted earnings per share of 75-95 cents. The projection suggests a decline from adjusted earnings of $1.85 recorded in 2023. Management had earlier envisioned an adjusted EPS of 95 cents to $1.35 for 2024.
For the third quarter of 2024, the company expects revenues between $430 million and $465 million, which suggests a decline of 14% to 7% from the year-ago quarter&#39;s reported level. NUS expects adjusted earnings in the band of 15-25 cents a share in the third quarter compared with 56 cents recorded in the same period last year.
<h3>Estimates Lose Sheen</h3>
The Zacks Consensus Estimate for 2024 earnings per share has declined from $1.10 to 78 cents over the past 30 days. The consensus estimate for the third-quarter EPS has tumbled from 48 to 20 cents in the same time frame. This downward adjustment reflects a negative sentiment among analysts and suggests potential challenges in achieving projected profitability.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/37/74746.jpg?v=388068093" />
Image Source: Zacks Investment Research
<h3>Wrapping Up</h3>
Nu Skin is navigating through a turbulent period, with its stock performance reflecting the ongoing macroeconomic and industry-specific challenges. While the company is actively pursuing strategic initiatives to reinvigorate its market presence and drive growth through new product launches and the strength of its Rhyz business, these efforts may take time to bear fruit. In the near term, the combination of persistent headwinds and tighter guidance suggests that Nu Skin faces a difficult road ahead.
Investors should remain cautious, keeping a close eye on how the company manages these challenges and whether its strategic initiatives can offset the current pressures. Nu Skin presently carries a Zacks Rank #5 (Strong Sell).
<h3>Better-Ranked Staple Bets</h3>
The Chef&#39;s Warehouse (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chef#NASDAQ">CHEF</a>), which distributes specialty food and center-of-the-plate products, has a trailing four-quarter earnings surprise of 33.7%, on average. CHEF currently sports a Zacks Rank #1 (Strong Buy).
The Zacks Consensus Estimate for The Chef&#39;s Warehouse&#39;s current financial-year sales and earnings calls for growth of 9.7% and 12.6%, respectively, from the prior-year reported level.
Vital Farms (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vitl#NASDAQ">VITL</a>) offers a range of produced pasture-raised foods. It currently carries a Zacks Rank #2 (Buy). VITL has a trailing four-quarter earnings surprise of 82.5%, on average.
The Zacks Consensus Estimate for Vital Farms&#39; current financial-year earnings indicates growth of 72.9% from the year-ago reported numbers.
Nomad Foods (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nomd#NYSE">NOMD</a>), carrying a Zacks Rank #2, manufactures and distributes frozen foods. NOMD has a trailing four-quarter earnings surprise of 3.1%, on average.
The Zacks Consensus Estimate for Nomad Foods&#39; current financial-year sales and earnings implies growth of 4.3% and 11.5%, respectively, from the prior-year reported level.
<a href="https://www.zacks.com/stock/news/2324418/nu-skin-nus-down-28-in-3-months-what-s-the-next-best-move?cid=CS-BENZ-FT-analyst_blog|rank_focused-2324418">To read this article on Zacks.com click here.</a>

CHEF

NOMD

VITL

Nu Skin Down 28% in 3 Months: What's the Next Best Move?

DA Davidson analyst Linda Bolton Weiser maintains Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) with a Neutral and lowers the price target from $12.5 to $11.

DA Davidson Maintains Neutral on Nu Skin Enterprises, Lowers Price Target to $11

Nu Skin Enterprises shares are trading lower. Citigroup maintained a Neutral rating on the stock and lowered its price target from $14 to $11.5.

Citigroup analyst Chasen Bender maintains Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) with a Neutral and lowers the price target from $14 to $11.5.

Citigroup Maintains Neutral on Nu Skin Enterprises, Lowers Price Target to $11.5

Nu Skin Enterprises Revises FY24 Revenue Forecast From $1.73B - $1.87B To $1.73B - $1.81B (Est $1.77B), Cuts Adj EPS Outlook From $0.95 - $1.35 To $0.75 - $0.95 (Est $1.10)

Nu Skin Enterprises Expects Q3 Revenue Of $430M - $465M, Est $459.86M; Adj EPS Of $0.15 - $0.25, Est $0.42

Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.17 by 23.53 percent. This is a 61.11 percent decrease over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $439.081 million which beat the analyst consensus estimate of $431.871 million by 1.67 percent. This is a 12.23 percent decrease over sales of $500.257 million the same period last year.

Nu Skin Enterprises Q2 2024 Adj. EPS $0.21 Beats $0.17 Estimate, Sales $439.081M Beat $431.871M Estimate

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he likes Pure Storage, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>), adding that it is a &#8220;<a href="https://www.benzinga.com/quote/PSTG/earnings">fabulous&#8221; company</a>.
Pure Storage is expected to host a conference call on Wednesday, May 29 to discuss its financial results for the first quarter fiscal year 2025.
&#8220;Anything connected with EVs right now is a no go,&#8221; Cramer said when asked about Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>).
On May 1, Albemarle reported mixed results for the first quarter.
When asked about AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>), he said, &#8220;We've been behind AeroVironment forever, and the reason is that they make drones that are much less expensive than the other stuff the military buys.&#8221;
On March 4, AeroVironment said third-quarter revenue increased 39% year-over-year to $186.6 million, which beat the consensus estimate of $170.625 million.
The &#8220;Mad Money&#8221; host said Nu Skin Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) is an &#8220;overvalued&#8221; stock even at these prices.
On May 8, Nu Skin Enterprises posted weaker-than-expected quarterly results.
AllianceBernstein Holding L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>) is a &#8220;very well-run&#8221; company, Cramer said. &#8220;Always surprised that it is as inexpensive as it is.&#8221;
On April 25, AllianceBernstein posted better-than-expected first-quarter earnings results.
When asked about MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Jim Cramer said, &#8220;If you want Bitcoin, don't buy MicroStrategy.&#8221;
On April 29, MicroStrategy reported worse-than-expected first-quarter financial results.
&#8220;These are infrastructure plays that are working because that money is starting to pour in from the federal government. That's why that's a winner,&#8221; Cramer said when asked about Sterling Infrastructure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>).
On May 6, Sterling Infrastructure reported better-than-expected first-quarter financial results.
Price Action:
<ul>
<li>AllianceBernstein shares rose 0.2% to settle at $32.65 on Monday.</li>
<li>Pure Storage shares fell 0.2% to close at $54.33.</li>
<li>Albemarle shares rose 1.5% to settle at $131.51 on Monday.</li>
<li>MicroStrategy shares gained 5.6% to settle at $1,245.96.</li>
<li>AeroVironment shares rose 0.4% to close at $187.28 on Monday.</li>
<li>Sterling Infrastructure shares fell 0.6% to settle at $128.08 on Monday.</li>
<li>Nu Skin shares gained 2.2% to close at $13.51.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/news/24/05/38788200/top-5-tech-stocks-that-may-plunge-in-q2">Top 5 Tech Stocks That May Plunge In Q2</a>

Media

AVAV

MSTR

PSTG

STRL

Jim Cramer Says Nu Skin Is 'Overvalued,' Praises 'Fabulous' Pure Storage

DA Davidson analyst Linda Bolton Weiser maintains Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) with a Neutral and lowers the price target from $15.5 to $12.5.

DA Davidson Maintains Neutral on Nu Skin Enterprises, Lowers Price Target to $12.5

Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.05 by 120 percent. The company reported quarterly sales of $417.300 million which missed the analyst consensus estimate of $426.561 million by 2.17 percent. This is a 13.33 percent decrease over sales of $481.462 million the same period last year.

Nu Skin Enterprises Q1 2024 Adj EPS $(0.01) Misses $0.05 Estimate, Sales $417.300M Miss $426.561M Estimate

On March 06, 2024, Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) will distribute a dividend payout of $0.06 per share, equating to an annualized dividend yield of 1.38%. Shareholders who owned the stock before the ex-dividend date on February 23, 2024 will receive this payout.
<h3>Nu Skin Enterprises Recent Dividend Payouts</h3>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style><table>
<thead>
<tr>
<th>Ex-Date</th>
<th style="text-align: right;">Payments per year</th>
<th>Dividend</th>
<th>Yield</th>
<th>Announced</th>
<th>Record</th>
<th>Payable</th>
</tr>
</thead>
<tbody>
<tr>
<td>2024-02-23</td>
<td style="text-align: right;">4</td>
<td>$0.06</td>
<td>1.38%</td>
<td>2024-02-14</td>
<td>2024-02-26</td>
<td>2024-03-06</td>
</tr>
<tr>
<td>2023-11-22</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>8.21%</td>
<td>2023-11-01</td>
<td>2023-11-24</td>
<td>2023-12-06</td>
</tr>
<tr>
<td>2023-08-24</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>5.31%</td>
<td>2023-08-01</td>
<td>2023-08-25</td>
<td>2023-09-06</td>
</tr>
<tr>
<td>2023-05-25</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.91%</td>
<td>2023-05-03</td>
<td>2023-05-26</td>
<td>2023-06-07</td>
</tr>
<tr>
<td>2023-02-24</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.6%</td>
<td>2023-02-15</td>
<td>2023-02-27</td>
<td>2023-03-08</td>
</tr>
<tr>
<td>2022-11-23</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.93%</td>
<td>2022-11-02</td>
<td>2022-11-25</td>
<td>2022-12-07</td>
</tr>
<tr>
<td>2022-08-25</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.43%</td>
<td>2022-08-04</td>
<td>2022-08-26</td>
<td>2022-09-07</td>
</tr>
<tr>
<td>2022-05-26</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.45%</td>
<td>2022-05-04</td>
<td>2022-05-27</td>
<td>2022-06-08</td>
</tr>
<tr>
<td>2022-02-25</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.1%</td>
<td>2022-02-16</td>
<td>2022-02-28</td>
<td>2022-03-09</td>
</tr>
<tr>
<td>2021-11-24</td>
<td style="text-align: right;">4</td>
<td>$0.38</td>
<td>3.78%</td>
<td>2021-11-03</td>
<td>2021-11-26</td>
<td>2021-12-08</td>
</tr>
<tr>
<td>2021-08-26</td>
<td style="text-align: right;">4</td>
<td>$0.38</td>
<td>2.8%</td>
<td>2021-08-04</td>
<td>2021-08-27</td>
<td>2021-09-08</td>
</tr>
<tr>
<td>2021-05-27</td>
<td style="text-align: right;">4</td>
<td>$0.38</td>
<td>2.92%</td>
<td>2021-05-05</td>
<td>2021-05-28</td>
<td>2021-06-09</td>
</tr>
</tbody>
</table>
Nu Skin Enterprises lags behind its industry peers in terms of dividend yield, with Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) surpassing it with a higher annualized dividend yield of 17.00%.
<h3>Analyzing Nu Skin Enterprises Financial Health</h3>
Companies that pay out steady cash dividends are attractive to income-seeking investors, and companies that are financially healthy tend to maintain their dividend payout schedule. For this reason, investors can find it insightful to see if a company has been increasing or decreasing their dividend payout schedule and if their earnings are growing. 
<h3>YoY Growth in Dividend Per Share</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1709737512_0.png" alt="dividend chart graph" />
Investors witnessed an upward trajectory in the company's dividend per share between 2020 and 2023. The dividend per share rose from $1.50 to $1.56, indicating the company's dedication to enhancing shareholder value through increased dividends.
<h3>YoY Earnings Growth For Nu Skin Enterprises</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1709737512_1.png" alt="earning chart graph" />
From 2020 to 2023, Nu Skin Enterprises experienced a decrease in earnings per share, dropping from $2.97 to $2.36. This declining earnings trend may be worrisome for income-seeking investors, as it indicates a potential impact on the company's ability to sustain or increase its cash dividend payouts. Further analysis is necessary to understand the underlying reasons for this decrease.
<h3>Recap</h3>
In this article, we explore the recent dividend payout of Nu Skin Enterprises and its significance for shareholders. The company has decided to distribute a dividend of $0.06 per share today, which equates to an annualized dividend yield of 1.38%.
Nu Skin Enterprises lags behind its industry peers in terms of dividend yield, with Medifast surpassing it with a higher annualized dividend yield of 17.00%.
With dividend per share increasing and earnings per share decreasing from 2020 to 2023, Nu Skin Enterprises seems to be emphasizing the distribution of profits to investors despite the decline in profitability.
To stay informed about changes in financials or dividend disbursements, investors should pay close attention to the company's performance in the upcoming quarters.
[See current stock movements Nu Skin Enterprises on Benzinga.](https://www.benzinga.com/quote/Nu Skin Enterprises (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nus#NYSE">NUS</a>))
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dividends

Navigating Challenges and Investor Rewards: Nu Skin Enterprises Ensures Steady Distribution amidst Changing Profits

DA Davidson lowered the firm's price target on Nu Skin (NUS) to $7 from $11 and keeps a Neutral rating on the shares. The firm cites the company's ...

Nu Skin price target lowered to $7 from $11 at DA Davidson

Nu Skin Enterprises rises 4.3%, sells Mavely platform for $250 million

Nu Skin ( ($NUS) ) has issued an update. Nu Skin Enterprises announced the sale of its Mavely affiliate marketing technology platform to Later for ...

Nu Skin Sells Mavely Platform to Later for $250M

Nu Skin (NUS) Enterprises announced that its Rhyz subsidiary completed a strategic transaction with Later, a portfolio company of Summit Partners. ...

Nu Skin's Rhyz completes sale of Mavely for $250M

Check out this morning's top movers from around Wall Street, compiled by The Fly.&nbsp; HIGHER – N2OFF (NITO) up 96% after signing a binding letter...

Morning Movers: U.S. Steel falls after President Biden blocks Nippon deal

Nu Skin (NUS) is up 16.6%, or $1.09 to $7.65. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

Nu Skin rises 16.6%

Nu Skin (NUS) is up 22.4%, or $1.47 to $8.03. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

Nu Skin rises 22.4%

Nu Skin (NUS) is up 24.8%, or $1.63 to $8.19. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

Nu Skin rises 24.8%

Wall Street is pacing for its first win in 2025, though all three major benchmarks are lower for the week.

Wall Street Higher; Still Pacing For Weekly Loss

After Nu Skin (NUS) announced the sale of its marketing tech platform business, Mavely, to Summit Partners portfolio company Later, Jefferies noted...

Nu Skin generated about five-times return on Mavely investment, says Jefferies

CTSO

KNSL

NITO

TAYD

Press Releases

Nu Skin Enterprises Appoints Mark A. Zorko to Board of Directors

Social Media

New Data: Gen Z Most Likely to Trust Influencer Gift Recommendations, but Need the Most Touchpoints for a Sell

Nu Skin Enterprises to Announce Third Quarter 2024 Financial Results

Mavely Streamlines Creator Experience from Post to Purchase with New LinkDM and Button Partnerships and MyShop Upgrades

Nu Skin Introduces MYND360™, a New Line of Clinically Proven Supplements and Topicals for Mental Well-Being

Later Drives Full-Funnel Influencer Marketing Impact with New Affiliate Campaign Capabilities, Leveraging a Strategic Partnership with Mavely

Nu Skin Enterprises Announces Quarterly Dividend

Nu Skin Enterprises Reports Third Quarter Results

Nu Skin Enterprises Announces Strategic Transaction of Mavely for $250 Million

Later Acquires Mavely for $250 Million, Unlocking New Opportunities for Marketers and Creators to Maximize their Return on Social

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Honest Co

Interparfums

Kenvue

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Enter

Safety Shot

The Beauty Health Company - Class A Common Stock

Beauty Health

Unilever

Usana Health Sciences

Veru

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Comments

Nu Skin Enterprises

Nu Skin Enterprises (NUS) Options

Nu Skin Enterprises (NYSE:NUS) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL